|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Pulmonary Hypertension
Pulmonary hypertension (PH) is increased pressure in the pulmonary arteries. These arteries carry blood from your heart to your lungs to pick up oxygen.
Changes in the pulmonary arteries make it increasingly difficult for the heart to push blood through the arteries and into the lungs. As a result, the heart works harder, and the right ventricle becomes strained and weak. The heart may become so weak that it can't pump enough blood to the lungs, often leading to heart failure.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Pulmonary Hypertension Study A2301
The purpose of this clinical trial is to determine the benefits and safety of a Novartis investigative drug as an add-on therapy in the treatment of people with severe pulmonary arterial hypertension.
An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: Participants will be asked to visit the study center over a 6 month period. Protocol Number: CQTI571A2301 |